BioHarvest Sciences Inc. Common Stock (BHST)
Automate Your Wheel Strategy on BHST
With Tiblio's Option Bot, you can configure your own wheel strategy including BHST - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BHST
- Rev/Share 1.5975
- Book/Share -0.0506
- PB -136.0833
- Debt/Equity -21.1986
- CurrentRatio 0.5093
- ROIC -0.4135
- MktCap 119214576.0
- FreeCF/Share -0.5669
- PFCF -12.1355
- PE -13.7615
- Debt/Assets 0.6984
- DivYield 0
- ROE -3.0679
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | BHST | Craig Hallum | -- | Buy | -- | $15 | May 5, 2025 |
| Initiation | BHST | Maxim Group | -- | Buy | -- | $12 | Dec. 18, 2024 |
News
What Makes BioHarvest Sciences Inc. (BHST) a Good Fit for 'Trend Investing'
Published: June 03, 2025 by: Zacks Investment Research
Sentiment: Positive
BioHarvest Sciences Inc. (BHST) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Read More
BioHarvest enters fragrance industry with AI edge - ICYMI
Published: May 23, 2025 by: Proactive Investors
Sentiment: Positive
BioHarvest Sciences Inc. (NASDAQ:BHST) earlier this week announced a new contract targeting the plant-based fragrance compound market, using its proprietary botanical synthesis platform. CEO Ilan Sobel said the contract focuses on a rare plant under threat from overharvesting and habitat loss.
Read More
BioHarvest inks fragrance compound deal in move into multi-billion-dollar scents market
Published: May 21, 2025 by: Proactive Investors
Sentiment: Positive
BioHarvest Sciences Inc. (NASDAQ:BHST) said it has signed a contract to develop a plant-based fragrance compound using its patented Botanical Synthesis technology, marking the company's entry into the multi-billion-dollar fragrance and scents industry. The contract, with an undisclosed commercial partner, targets the development of a compound derived from a threatened plant species facing overharvesting and habitat loss.
Read More
BioHarvest Secures New CDMO Contract to Develop Plant-based Fragrance Compound
Published: May 21, 2025 by: Newsfile Corp
Sentiment: Neutral
First CDMO Project to Utilize In-house AI Tools for Discovery of Plant Cell Targets for the Botanical Synthesis Process Rehovot, Israel--(Newsfile Corp. - May 21, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's Botanical Synthesis CDMO Services division has secured a new contract to develop a plant-based fragrance compound derived from a plant that is under significant threat due to over harvesting and habitat loss. This agreement is with a new commercial partner targeting the multi-billion-dollar fragrance and scents market.
Read More
BioHarvest Sciences advances CDMO deal with major pharmaceutical company - ICYMI
Published: May 17, 2025 by: Proactive Investors
Sentiment: Positive
BioHarvest Sciences Inc. (NASDAQ:BHST) CEO Ilan Sobel joined Proactive to discuss the company's transition to stage two of its partnership with a pharmaceutical company. This marks a key milestone in the development of plant-derived biological materials for use in approved drugs.
Read More
BioHarvest Sciences Inc. (BHST) Q1 2025 Earnings Call Transcript
Published: May 15, 2025 by: Seeking Alpha
Sentiment: Neutral
BioHarvest Sciences Inc. (NASDAQ:BHST ) Q1 2025 Earnings Conference Call May 15, 2025 4:30 PM ET Company Participants Ilan Sobel - CEO Bar Dichter - CFO Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Amit Dayal - H.C. Wainwright Susan Anderson - Canaccord Genuity Nicholas Sherwood - Maxim Group Hunter Diamond - Diamond Equity Research Operator Greetings, and welcome to the BioHarvest Sciences First Quarter 2025 Corporate Update Conference Call.
Read More
BioHarvest Sciences Inc. (BHST) Reports Q1 Loss, Tops Revenue Estimates
Published: May 15, 2025 by: Zacks Investment Research
Sentiment: Negative
BioHarvest Sciences Inc. (BHST) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.35 per share a year ago.
Read More
BioHarvest Sciences advances CDMO project with Nasdaq-listed pharmaceutical company to next stage
Published: May 12, 2025 by: Proactive Investors
Sentiment: Positive
BioHarvest Sciences Inc. (NASDAQ:BHST) announced the successful transition of its contract development and manufacturing (CDMO) partnership with a Nasdaq-listed pharmaceutical company from Stage 1 to Stage 2, further validating its Botanical Synthesis technology for pharmaceutical applications. The contract, which began in early 2024, aims to develop a compound used in an approved drug product.
Read More
BioHarvest Announces Completion of Stage 1 Development for CDMO Contract with Nasdaq-Listed Pharmaceutical Company
Published: May 12, 2025 by: Newsfile Corp
Sentiment: Neutral
Successful Progression Validates Botanical Synthesis Platform for a Variety of Molecule Types Rehovot, Israel--(Newsfile Corp. - May 12, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that the Company's previously announced CDMO contract with a Nasdaq-listed pharmaceutical company has progressed from Stage 1 to Stage 2 - providing further validation of the versatility of the Company's Botanical Synthesis platform to develop active pharmaceutical compounds while concurrently paving the road for potential future volume manufacturing. Stage 1 of the contract, launched in early 2024, focused …
Read More
BioHarvest Sciences Inc. (BHST) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
BioHarvest Sciences Inc. (BHST) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Read More
BioHarvest Sciences to Host First Quarter 2025 Earnings Call on May 15 at 4:30 p.m. Eastern Time
Published: May 01, 2025 by: Newsfile Corp
Sentiment: Neutral
Rehovot, Israel--(Newsfile Corp. - May 1, 2025) - BioHarvest Sciences Inc. (NASDAQ: BHST) (FSE: 8MV0) ("BioHarvest" or the "Company"), a company pioneering its patented Botanical Synthesis technology platform, today announced that it will release financial results for the first quarter ended March 31, 2025 after market close on Thursday, May 15, 2025. Management will host an investor conference call and webcast at 4:30 p.m.
Read More
Strength Seen in BioHarvest Sciences Inc. (BHST): Can Its 12.7% Jump Turn into More Strength?
Published: March 17, 2025 by: Zacks Investment Research
Sentiment: Positive
BioHarvest Sciences Inc. (BHST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Read More
About BioHarvest Sciences Inc. Common Stock (BHST)
- IPO Date
- Website https://www.bioharvest.com
- Industry Agricultural - Commodities/Milling
- CEO Mr. Ilan Sobel
- Employees 87